Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32319-0 · Cited by 4,974
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationOverman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836
Self-citationDiagnosis and Treatment of Metastatic Colorectal Cancer: A Review
Biller, L. H., & Schrag, D. (2021) · JAMA · doi:10.1001/jama.2021.0106 · Cited by 2,604
Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1101-6 · Cited by 2,467
“⑤ The efficacy and safety of TAS-102 are evaluated on the basis of J-003 study and RECOURSE study.”
BackgroundInfluentialSelf-citationPatient-derived organoids model treatment response of metastatic gastrointestinal cancers
Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., et al. (2018) · Science · doi:10.1126/science.aao2774 · Cited by 2,096
Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Self-citationCervantes, A., Adam, R., Roselló, S., Arnold, D., Normanno, N., Taïeb, J., Seligmann, J., De Baere, T., Osterlund, P., Yoshino, T., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.003 · Cited by 1,796
Self-citationKRAS G12C Inhibition with Sotorasib in Advanced Solid Tumors
Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Al-Hawary, M. M., Arain, M. A., Chen, Y.-J., Ciombor, K. K., Cohen, S., Cooper, H. S., Deming, D., Farkas, L., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0012 · Cited by 1,696
Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Cederquist, L., Chan, E., Chen, Y.-J., Cooper, H. S., Deming, D., Engstrom, P. F., Enzinger, P. C., Fichera, A., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0036 · Cited by 1,330
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Sartore-Bianchi, A., Trusolino, L., Martino, C., Bencardino, K., Lonardi, S., Bergamo, F., Zagonel, V., Leone, F., Depetris, I., Martinelli, E., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00150-9 · Cited by 1,016
5-fluorouracil and other fluoropyrimidines in colorectal cancer: Past, present and future
Vodenkova, S., Buchler, T., Cervena, K., Veskrnova, V., Vodicka, P., & Vymetalkova, V. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107447 · Cited by 956
Cherny, N. I., Sullivan, R., Dafni, U., Kerst, J. M., Sobrero, A., Zielinski, C., de Vries, E. G. E., & Piccart, M. J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv249 · Cited by 818
“81) 2 [110]”
Self-citationFrom tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Hesketh, P. J., Kris, M. G., Basch, E., Bohlke, K., Barbour, S. Y., Clark-Snow, R. A., Danso, M. A., Dennis, K., Dupuis, L. L., Dusetzina, S. B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4789 · Cited by 628
Eng, C., Kim, T. W., Bendell, J., Argilés, G., Tebbutt, N. C., Di Bartolomeo, M., Falcone, A., Fakih, M., Kozloff, M., Segal, N. H., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30027-0 · Cited by 577
Self-citationYoshino, T., Arnold, D., Taniguchi, H., Pentheroudakis, G., Yamazaki, K., Xu, R.-H., Kim, T. W., Ismail, F., Tan, I. B., Yeh, K.-H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx738 · Cited by 573
Self-citationClinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J., & Cervantes, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 528
Self-citationAdagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C
Yaeger, R., Weiss, J., Pelster, M. S., Spira, A. I., Barve, M., Ou, S.-H. I., Leal, T. A., Bekaii-Saab, T. S., Paweletz, C. P., Heavey, G. A., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2212419 · Cited by 527
Pharmacologic resistance in colorectal cancer: a review
Hammond, W. A., Swaika, A., & Mody, K. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015614530 · Cited by 519
Shitara, K., Doi, T., Dvorkin, M., Mansoor, W., Arkenau, H.-T., Prokharau, A., Alsina, M., Ghidini, M., Faustino, C., Gorbunova, V., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30739-3 · Cited by 511
Self-citationHainsworth, J. D., Meric-Bernstam, F., Swanton, C., Hurwitz, H., Spigel, D. R., Sweeney, C., Burris, H. A., Bose, R., Yoo, B., Stein, A., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3780 · Cited by 506
“Bladder 9 1 (11) 2 (22) 2 (22) 33 (8 to 70) Pancreas 9 0 2 (22) 1 (11) 22 (3 to 60) Biliary 7 0 2 (29) 3 (38) 29 (4 to 71) Ovary 8 0 1 (13) 0 13 (0 to 53) Uterus 7 0 0 0 0 Salivary gland 5 0 4 (80) 0 80 (28 to .”
Eng, C., Yoshino, T., Ruíz-García, E., Mostafa, N., Cann, C. G., O'Brian, B., Benny, A., Perez, R. O., & Cremolini, C. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00360-x · Cited by 449
Self-citationTrifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer
Prager, G. W., Taieb, J., Fakih, M., Ciardiello, F., Van Cutsem, E., Elez, E., Cruz, F. M., Wyrwicz, L., Stroyakovskiy, D., Pápai, Z., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2214963 · Cited by 467
Self-citationSubbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J., Takeda, M., Ohe, Y., Khan, S., Ohashi, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00541-1 · Cited by 449
Siena, S., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Fakih, M., Elez, E., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00086-3 · Cited by 422
Self-citationLi, J., Qin, S., Xu, R.-H., Shen, L., Xu, J., Bai, Y., Yang, L., Deng, Y., Chen, Z.-D., Zhong, H., et al. (2018) · JAMA · doi:10.1001/jama.2018.7855 · Cited by 425
Cremolini, C., Rossini, D., Dell’Aquila, E., Lonardi, S., Conca, E., Del Re, M., Busico, A., Pietrantonio, F., Danesi, R., Aprile, G., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2018.5080 · Cited by 424
Self-citationColon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology
Benson, A. B., Venook, A. P., Adam, M., Chang, G., Chen, Y.-J., Ciombor, K. K., Cohen, S. A., Cooper, H. S., Deming, D., Garrido-Laguna, I., et al. (2024) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2024.0029 · Cited by 371
Chen, E. X., Jonker, D. J., Loree, J. M., Kennecke, H. F., Berry, S. R., Couture, F., Ahmad, C. E., Goffin, J. R., Kavan, P., Harb, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0910 · Cited by 392
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
Fakih, M. G., Salvatore, L., Esaki, T., Modest, D. P., Lopez-Bravo, D. P., Taieb, J., Karamouzis, M. V., Ruiz-Garcia, E., Kim, T.-W., Kuboki, Y., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2308795 · Cited by 398
Dasari, A., Lonardi, S., Garcia-Carbonero, R., Elez, E., Yoshino, T., Sobrero, A., Yao, J., García-Alfonso, P., Kocsis, J., Cubillo Gracian, A., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00772-9 · Cited by 368
Self-citationDueland, S., Syversveen, T., Solheim, J. M., Solberg, S., Grut, H., Bjørnbeth, B. A., Hagness, M., & Line, P.-D. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000003404 · Cited by 360
Treatment sequencing in metastatic colorectal cancer
Modest, D. P., Pant, S., & Sartore-Bianchi, A. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.12.019 · Cited by 329
Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., Falchook, G. S., Han, S.-W., Heinemann, V., Muro, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00605-7 · Cited by 320
Self-citationParikh, A. R., Szabolcs, A., Allen, J. N., Clark, J. W., Wo, J. Y., Raabe, M., Thel, H., Hoyos, D., Mehta, A., Arshad, S., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00269-7 · Cited by 294
Sartore-Bianchi, A., Pietrantonio, F., Lonardi, S., Mussolin, B., Rua, F., Crisafulli, G., Bartolini, A., Fenocchio, E., Amatu, A., Manca, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01886-0 · Cited by 268
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
Xu, J., Kim, T. W., Shen, L., Sriuranpong, V., Pan, H., Xu, R., Guo, W., Han, S.-W., Liu, T., Park, Y. S., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.3245 · Cited by 259
Fabrizio, D. A., George Jr, T. J., Dunne, R. F., Frampton, G., Sun, J., Gowen, K., Kennedy, M., Greenbowe, J., Schrock, A. B., Hezel, A. F., et al. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.05.06 · Cited by 260
Strickler, J. H., Cercek, A., Siena, S., André, T., Ng, K., Van Cutsem, E., Wu, C., Paulson, A. S., Hubbard, J. M., Coveler, A. L., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00150-x · Cited by 259
Self-citationA comprehensive framework for early-onset colorectal cancer research
Eng, C., Jácome, A. A., Agarwal, R., Hayat, M. H., Byndloss, M. X., Holowatyj, A. N., Bailey, C., & Lieu, C. H. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00588-x · Cited by 241
S3-Leitlinie – Kolorektales Karzinom: Langversion 2.0 – November 2017–AWMF-Registernummer: 021/007OL
Schmiegel, W., Buchberger, B., Follmann, M., Graeven, U., Heinemann, V., Langer, T., Nothacker, M., Porschen, R., Rödel, C., Rösch, T., et al. (2017) · Zeitschrift für Gastroenterologie · doi:10.1055/s-0043-121106 · Cited by 241
Advances in immunotherapy for colorectal cancer: a review
Golshani, G., & Zhang, Y. (2020) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284820917527 · Cited by 236
Precision oncology in metastatic colorectal cancer — from biology to medicine
Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 239
Self-citationPfeiffer, P., Yilmaz, M., Möller, S., Zitnjak, D., Krogh, M., Petersen, L. N., Poulsen, L. Ø., Winther, S. B., Thomsen, K. G., & Qvortrup, C. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30827-7 · Cited by 232
Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231
Self-citationMartinelli, E., Martini, G., Famiglietti, V., Troiani, T., Napolitano, S., Pietrantonio, F., Ciardiello, D., Terminiello, M., Borrelli, C., Vitiello, P. P., et al. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.2915 · Cited by 182
Self-citationKuboki, Y., Nishina, T., Shinozaki, E., Yamazaki, K., Shitara, K., Okamoto, W., Kajiwara, T., Matsumoto, T., Tsushima, T., Mochizuki, N., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30425-4 · Cited by 176
Self-citationYoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178
Self-citationPD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Lin, K. X., Istl, A. C., Quan, D., Skaro, A. I., Tang, E. S.-T., & Zheng, X. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03520-5 · Cited by 178
TAS-102, a novel antitumor agent: A review of the mechanism of action
Lenz, H.-J., Stintzing, S., & Loupakis, F. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.001 · Cited by 163
Self-citationTaniguchi, H., Nakamura, Y., Kotani, D., Yukami, H., Mishima, S., Sawada, K., Shirasu, H., Ebi, H., Yamanaka, T., Aleshin, A. A., et al. (2021) · Cancer Science · doi:10.1111/cas.14926 · Cited by 182
Self-citationUnger, J. M., Moseley, A. B., Cheung, C. K., Osarogiagbon, R. U., Symington, B. E., Ramsey, S. D., & Hershman, D. L. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.02602 · Cited by 173
Bullock, A. J., Schlechter, B. L., Fakih, M., Tsimberidou, A. M., Grossman, J. E., Gordon, M. S., Wilky, B. A., Pimentel, A., Mahadevan, D., Balmanoukian, A. S., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03083-7 · Cited by 181
Self-citationLévi, F., Boige, V., Hebbar, M., Smith, D. M., Lepère, C., Focan, C., Karaboué, A., Guimbaud, R., Carvalho, C. T., Tumolo, S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv548 · Cited by 164
Towards precision oncology with patient-derived xenografts
Zanella, E. R., Grassi, E., & Trusolino, L. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00682-6 · Cited by 165
Datta, J., Narayan, R. R., Kemeny, N. E., & D'Angelica, M. I. (2019) · JAMA Surgery · doi:10.1001/jamasurg.2019.1694 · Cited by 157
Current status of immunotherapy in metastatic colorectal cancer
Wróbel, P., & Ahmed, S. (2018) · International Journal of Colorectal Disease · doi:10.1007/s00384-018-3202-8 · Cited by 148
Limagne, E., Thibaudin, M., Nuttin, L., Spill, A., Derangère, V., Fumet, J.-D., Amellal, N., Peranzoni, E., Cattan, V., & Ghiringhelli, F. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0228 · Cited by 142
Phelip, J., Tougeron, D., Léonard, D., Benhaïm, L., Desolneux, G., Dupré, A., Michel, P., Penna, C., Tournigand, C., Louvet, C., et al. (2019) · Digestive and Liver Disease · doi:10.1016/j.dld.2019.05.035 · Cited by 161
Gollins, S., Moran, B. J., Adams, R., Cunningham, C., Bach, S. P., Myint, A. S., Renehan, A. G., Karandikar, S. S., Goh, V., Prezzi, D., et al. (2017) · Colorectal Disease · doi:10.1111/codi.13705 · Cited by 153
Montagut, C., Argilés, G., Ciardiello, F., Poulsen, T. T., Dienstmann, R., Kragh, M., Kopetz, S., Lindsted, T., Ding, C., Vidal, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5245 · Cited by 135
Self-citationSystemic Therapy for Colon Cancer
Wu, C. S.-Y. (2017) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2017.11.001 · Cited by 151
Morano, F., Raimondi, A., Pagani, F., Lonardi, S., Salvatore, L., Cremolini, C., Murgioni, S., Randon, G., Palermo, F., Antonuzzo, L., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02583 · Cited by 134
“Although these results should be interpreted with caution, given the nonrandomized nature of our trial, PFS and OS outcomes favorably compared with those achieved by the standard later line options available for patients with molecularly unselected mCRC.(33,34) Considering the poor prognosis of treatment-refractory di…”
ResultSelf-citationVogel, A., Hofheinz, R. D., Kubicka, S., & Arnold, D. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.007 · Cited by 134
Mettu, N. B., Ou, F.-S., Zemla, T. J., Halfdanarson, T. R., Lenz, H.-J., Breakstone, R. A., Boland, P. M., Crysler, O. V., Wu, C., Nixon, A. B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.49040 · Cited by 126
Self-citationCrisafulli, G., Bianchi, A. S., Lazzari, L., Pietrantonio, F., Amatu, A., Macagno, M., Barault, L., Cassingena, A., Bartolini, A., Luraghi, P., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1434 · Cited by 147
Sforza, V., Martinelli, E., Ciardiello, F., Gambardella, V., Napolitano, S., Martini, G., della Corte, C., Cardone, C., Ferrara, M. L., Reginelli, A., et al. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i28.6345 · Cited by 123
Cherny, N. I., de Vries, E. G. E., Dafni, U. G., Garrett-Mayer, E. S., McKernin, S. E., Piccart, M. J., Latino, N. J., Douillard, J.-Y., Schnipper, L. E., Somerfield, M. R., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00729 · Cited by 130
Self-citationStage IV Colorectal Cancer Management and Treatment
Dominguez, O. H., Yılmaz, S., & Steele, S. R. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12052072 · Cited by 135
Gonzalez-Exposito, R., Semiannikova, M., Griffiths, B., Khan, K., Barber, L. J., Woolston, A., Spain, G., von Loga, K., Challoner, B., Patel, R., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0575-3 · Cited by 120
Fakih, M., Raghav, K. P. S., Chang, D. Z., Larson, T., Cohn, A. L., Huyck, T. K., Cosgrove, D., Fiorillo, J. A., Tam, R., D’Adamo, D. R., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.101917 · Cited by 131
Virostko, J. M., Capasso, A., Yankeelov, T. E., & Goodgame, B. W. (2019) · Cancer · doi:10.1002/cncr.32347 · Cited by 134
Dueland, S., Grut, H., Syversveen, T., Hagness, M., & Line, P. (2019) · American Journal of Transplantation · doi:10.1111/ajt.15682 · Cited by 126
Evolving role of regorafenib for the treatment of advanced cancers
Grothey, A. F., Blay, J., Pavlakis, N., Yoshino, T., & Bruix, J. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.101993 · Cited by 125
Self-citationSystemic treatment for metastatic colorectal cancer
Leowattana, W., Leowattana, P., & Leowattana, T. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i10.1569 · Cited by 138
Cancers in Taiwan: Practical insight from epidemiology, treatments, biomarkers, and cost
Kuo, C.-N., Liao, Y., Kuo, L., Tsai, H., Chang, W., & Yen, Y. (2019) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2019.08.023 · Cited by 113
The Role of Cancer Stem Cells in Colorectal Cancer: From the Basics to Novel Clinical Trials
Hervieu, C., Christou, N., Battu, S., & Mathonnet, M. (2021) · Cancers · doi:10.3390/cancers13051092 · Cited by 122
Haag, G. M., Springfeld, C., Grün, B., Apostolidis, L., Zschäbitz, S., Dietrich, M., Berger, A.-K., Weber, T. F., Zoernig, I., Schaaf, M., et al. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.03.017 · Cited by 105
Moriwaki, T., Fukuoka, S., Taniguchi, H., Takashima, A., Kumekawa, Y., Kajiwara, T., Yamazaki, K., Esaki, T., Makiyama, C., Denda, T., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0275 · Cited by 108
Self-citationMiyamoto, Y., Suyama, K., & Baba, H. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18040752 · Cited by 106
Recent developments in the treatment of metastatic colorectal cancer
Loree, J. M., & Kopetz, S. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017714997 · Cited by 115
Liquid biopsies to monitor and direct cancer treatment in colorectal cancer
Mauri, G., Vitiello, P. P., Sogari, A., Crisafulli, G., Bianchi, A. S., Marsoni, S., Siena, S., & Bardelli, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01769-8 · Cited by 119
Kuboki, Y., Fakih, M., Strickler, J., Yaeger, R., Masuishi, T., Kim, E. J., Bestvina, C. M., Kopetz, S., Falchook, G. S., Langer, C., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02717-6 · Cited by 103
“3c). and overall survival of 6.4 months for regorafenib and 7.1 months for trifluridine–tipiracil 4,5 .”
InfluentialKawazoe, A., Xu, R., Alfonso, P. G., Passhak, M., Teng, H., Shergill, A. P., Gümüş, M., Qvortrup, C., Stintzing, S., Towns, K., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02736 · Cited by 119
Self-citationTosi, F., Sartore-Bianchi, A., Lonardi, S., Amatu, A., Leone, F., Ghezzi, S., Martino, C., Bencardino, K., Bonazzina, E., Bergamo, F., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.06.009 · Cited by 101
“These results are achieved in a heavily pretreated population in which standard therapeutic options such as regorafenib or trifluridine-tipiracil do not provide meaningful ORR.(11,12) Interestingly, we documented a sustained complete response (CR) still maintained at 7 years of follow-up (Supplemental Figure 2 in the…”
BackgroundXu, Y., Ju, L., Tong, J., Zhou, C.-M., & Yang, J.-J. (2020) · Scientific Reports · doi:10.1038/s41598-020-59115-y · Cited by 100
Le, D. T., Diaz, L. A., Kim, T. W., Cutsem, E. V., Geva, R., Jäger, D., Hara, H., Burge, M., O’Neil, B. H., Kavan, P., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2023.02.016 · Cited by 107
Self-citationBangi, E., Ang, C., Smibert, P., Uzilov, A. V., Teague, A., Antipin, Y., Chen, R., Hecht, C., Gruszczynski, N., Yon, W. J., et al. (2019) · Science Advances · doi:10.1126/sciadv.aav6528 · Cited by 112
Role of targeted therapy in metastatic colorectal cancer
Ohhara, Y., Fukuda, N., Takeuchi, S., Honma, R., Shimizu, Y., Kinoshita, I., & Dosaka-Akita, H. (2016) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v8.i9.642 · Cited by 96
Van Cutsem, E., Mayer, R. J., Laurent, S., Winkler, R., Grávalos, C., Benavides, M., Longo-Munoz, F., Portales, F., Ciardiello, F., Siena, S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2017.10.009 · Cited by 95
Self-citationIsambert, N., Hervieu, A., Rébé, C., Hennequin, A., Borg, C., Zanetta, S., Chevriaux, A., Richard, C., Dérangère, V., Limagne, E., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1474319 · Cited by 101
Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S. (2022) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_351354 · Cited by 95
HER2: An emerging target in colorectal cancer
Greally, M., Kelly, C. M., & Cercek, A. (2018) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2018.07.001 · Cited by 104
von Einem, J. C., Guenther, C., Volk, H., Grütz, G., Hirsch, D., Salat, C., Stoetzer, O., Nelson, P. J., Michl, M., Modest, D. P., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32230 · Cited by 93
New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer
Sánchez-Gundín, J., Fernández-Carballido, A. M., Valdivieso, L. M., Barreda-Hernández, D., & Torres‐Suárez, A. I. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.24453 · Cited by 100
Yarchoan, M., Huang, C., Zhu, Q., Ferguson, A. K., Durham, J. N., Anders, R. A., Thompson, E. D., Rozich, N. S., Thomas, D. L., Nauroth, J. M., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.2763 · Cited by 88
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.